Europe PMC requires Javascript to function effectively.

Either your web browser doesn't support Javascript or it is currently turned off. In the latter case, please turn on Javascript support in your web browser and reload this page.

Search life-sciences literature (45,104,931 articles, preprints and more)

Search results

1-25 of 85 results

Sort by:

Relevance ^{Relevance: This is determined based on a ranking of criteria including term frequency, rarity of term, recency of article, whether there is a Title or Author field match, etc.}

Times cited

Date

1 2 3 Next ...

Capmatinib efficacy for METex14 non-small cell lung cancer patients: Results of the IFCT-2104 CAPMATU study.
Ferreira M, Swalduz A, Greillier L, du Rusquec P, Curcio H, Raimbourg J, Toffart AC, Gounant V, Couraud S, De Chabot G, Friard S, Hureaux J, Jeannin G, Odier L, Ricordel C, Wislez M, Descarpentries C, Herbreteau G, Missy P, [...] Cortot AB
Lung Cancer, 196:107934, 24 Aug 2024
Cited by: 0 articles | PMID: 39277916
Add to export list
Faecalibaterium prausnitzii strain EXL01 boosts efficacy of immune checkpoint inhibitors.
Bredon M, Danne C, Pham HP, Ruffié P, Bessede A, Rolhion N, Creusot L, Brot L, Alonso I, Langella P, Derosa L, Cortot AB, Routy B, Zitvogel L, Segata N, Sokol H
Oncoimmunology, 13(1):2374954, 01 Jul 2024
Cited by: 1 article | PMID: 38957477 | PMCID: PMC11218805
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study.
Passaro A, Wang J, Wang Y, Lee SH, Melosky B, Shih JY, Wang J, Azuma K, Juan-Vidal O, Cobo M, Felip E, Girard N, Cortot AB, Califano R, Cappuzzo F, Owen S, Popat S, Tan JL, Salinas J, [...] MARIPOSA-2 Investigators
Ann Oncol, 35(1):77-90, 23 Oct 2023
Cited by: 40 articles | PMID: 37879444
Add to export list
MET variants with activating N-lobe mutations identified in hereditary papillary renal cell carcinomas still require ligand stimulation
Guérin C, Vinchent A, Fernandes M, Damour I, Laratte A, Tellier R, Estevam GO, Meneboo J, Villenet C, Descarpentries C, Fraser JS, Figeac M, Cortot AB, Rouleau E, Tulasne D
bioRxiv, 05 Nov 2023
Cited by: 0 articles | PPR: PPR753377
Add to export list Preprint
Histo-Molecular Factors of Response to Combined Chemotherapy and Immunotherapy in Non-Small Cell Lung Cancers.
Marchal M, Leroy V, Behal H, Dansin E, Paris N, Bordier S, Humez S, Escande F, Gauvain C, Cortot AB
Target Oncol, 18(6):927-939, 03 Nov 2023
Cited by: 1 article | PMID: 37921939 | PMCID: PMC10663251
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Characterization of 164 patients with NRAS mutated non-small cell lung cancer (NSCLC).
Dehem A, Mazieres J, Chour A, Guisier F, Ferreira M, Boussageon M, Girard N, Moro-Sibilot D, Cadranel J, Zalcman G, Ricordel C, Wislez M, Munck C, Poulet C, Gauvain C, Descarpentries C, Wasielewski E, Cortot AB, Baldacci S
Lung Cancer, 186:107393, 09 Oct 2023
Cited by: 1 article | PMID: 37839252
Add to export list
Transforming properties of MET receptor exon 14 skipping can be recapitulated by loss of the CBL ubiquitin ligase binding site.
Fernandes M, Paget S, Kherrouche Z, Truong MJ, Vinchent A, Meneboo JP, Sebda S, Werkmeister E, Descarpentries C, Figeac M, Cortot AB, Tulasne D
FEBS Lett, 597(18):2301-2315, 28 Jul 2023
Cited by: 2 articles | PMID: 37468447
Add to export list
Tepotinib Treatment in Patients With MET Exon 14-Skipping Non-Small Cell Lung Cancer: Long-term Follow-up of the VISION Phase 2 Nonrandomized Clinical Trial.
Mazieres J, Paik PK, Garassino MC, Le X, Sakai H, Veillon R, Smit EF, Cortot AB, Raskin J, Viteri S, Wu YL, Yang JCH, Ahn MJ, Ma R, Zhao J, O'Brate A, Berghoff K, Bruns R, Otto G, [...] Thomas M
JAMA Oncol, 9(9):1260-1266, 01 Sep 2023
Cited by: 23 articles | PMID: 37270698 | PMCID: PMC10240398
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Prolonging lung cancer response to EGFR inhibition by targeting the selective advantage of resistant cells
Brunet L, Alexandre D, Lee J, Blanquer-Rosselló MdM, Guernet A, Chhouri H, Kherrouche Z, Arabo A, Yao S, Godefroy D, Dehedin J, Li J, Duparc C, Jamme P, Vinchent A, Bérard C, Tulasne D, Arena S, Bardelli A, [...] Grumolato L
bioRxiv, 22 Jun 2023
Cited by: 0 articles | PPR: PPR680163
Add to export list Preprint
MET exon 14 skipping mutation is a hepatocyte growth factor (HGF)-dependent oncogenic driver in vitro and in humanised HGF knock-in mice.
Fernandes M, Hoggard B, Jamme P, Paget S, Truong MJ, Grégoire V, Vinchent A, Descarpentries C, Morabito A, Stanislovas J, Farage E, Meneboo JP, Sebda S, Bouchekioua-Bouzaghou K, Nollet M, Humez S, Perera T, Fromme P, Grumolato L, [...] Kherrouche Z
Mol Oncol, 17(11):2257-2274, 14 Jul 2023
Cited by: 4 articles | PMID: 36799689 | PMCID: PMC10620121
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
MET Exon 14 Skipping in NSCLC: A Systematic Literature Review of Epidemiology, Clinical Characteristics, and Outcomes.
Mazieres J, Vioix H, Pfeiffer BM, Campden RI, Chen Z, Heeg B, Cortot AB
Clin Lung Cancer, 24(6):483-497, 18 Jun 2023
Cited by: 15 articles | PMID: 37451931
Add to export list Review
Response to Capmatinib in a MET Fusion-positive Cholangiocarcinoma.
Turpin A, Descarpentries C, Grégoire V, Farchi O, Cortot AB, Jamme P
Oncologist, 28(1):80-83, 01 Jan 2023
Cited by: 7 articles | PMID: 36434677 | PMCID: PMC9847551
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
PD-1/PD-L1 inhibitor activity in patients with gene-rearrangement positive non-small cell lung cancer-an IMMUNOTARGET case series.
Mushtaq R, Cortot AB, Gautschi O, Mazieres J, Camidge DR
Transl Lung Cancer Res, 11(12):2412-2417, 01 Dec 2022
Cited by: 3 articles | PMID: 36636412 | PMCID: PMC9830270
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Brief Report: First-line Pembrolizumab in Metastatic Non-Small Cell Lung Cancer Habouring MET Exon 14 Skipping Mutation and PD-L1 ≥50% (GFPC 01-20 Study).
Guisier F, Descourt R, Babey H, Huchot E, Falchero L, Veillon R, Cortot AB, Tissot C, Chouaid C, Decroisette C
Clin Lung Cancer, 23(8):e545-e549, 17 Sep 2022
Cited by: 5 articles | PMID: 36210290
Add to export list
Paclitaxel-bevacizumab combination in advanced non-squamous non-small-cell lung cancer (NSCLC): AVATAX, a retrospective multicentric study.
Bilger G, Toffart AC, Darrason M, Duruisseaux M, Ulmer L, Wang P, Leprieur EG, Girard N, Massiani MA, Bore P, Descourt R, Pinsolle J, Valery S, Monnet I, Swalduz A, Tissot C, Fournel P, Baranzelli A, Cortot AB, Decroisette C
Ther Adv Med Oncol, 14:17588359221099399, 06 Jun 2022
Cited by: 6 articles | PMID: 35694190 | PMCID: PMC9174558
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Safety of Tepotinib in Patients With MET Exon 14 Skipping NSCLC and Recommendations for Management.
Veillon R, Sakai H, Sakai H, Le X, Felip E, Cortot AB, Smit EF, Park K, Griesinger F, Britschgi C, Wu YL, Melosky B, Baijal S, Jr GC, Sedova M, Berghoff K, Otto G, Paik PK
Clin Lung Cancer, 23(4):320-332, 17 Mar 2022
Cited by: 6 articles | PMID: 35466070 | PMCID: PMC10068910
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Lorlatinib for advanced anaplastic lymphoma kinase-positive non-small cell lung cancer: Results of the IFCT-1803 LORLATU cohort.
Baldacci S, Besse B, Avrillon V, Mennecier B, Mazieres J, Dubray-Longeras P, Cortot AB, Descourt R, Doubre H, Quantin X, Duruisseaux M, Monnet I, Moro-Sibilot D, Cadranel J, Clément-Duchêne C, Cousin S, Ricordel C, Merle P, Otto J, [...] Girard N
Eur J Cancer, 166:51-59, 09 Mar 2022
Cited by: 13 articles | PMID: 35278825
Add to export list
Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice.
Le X, Sakai H, Felip E, Veillon R, Garassino MC, Raskin J, Cortot AB, Viteri S, Mazieres J, Smit EF, Thomas M, Iams WT, Cho BC, Kim HR, Yang JC, Chen YM, Patel JD, Bestvina CM, Park K, [...] Paik PK
Clin Cancer Res, 28(6):1117-1126, 01 Mar 2022
Cited by: 44 articles | PMID: 34789481 | PMCID: PMC9365370
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Brigatinib for Pretreated, ALK-Positive, Advanced Non-Small-Cell Lung Cancers: Long-Term Follow-Up and Focus on Post-Brigatinib Lorlatinib Efficacy in the Multicenter, Real-World BrigALK2 Study.
Descourt R, Pérol M, Rousseau-Bussac G, Planchard D, Mennecier B, Wislez M, Cadranel J, Cortot AB, Guisier F, Galland L, Do P, Schott R, Dansin É, Arrondeau J, Auliac JB, Geier M, Chouaïd C
Cancers (Basel), 14(7):1751, 30 Mar 2022
Cited by: 3 articles | PMID: 35406523 | PMCID: PMC8997056
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Combination of Trastuzumab, Pertuzumab, and Docetaxel in Patients With Advanced Non-Small-Cell Lung Cancer Harboring HER2 Mutations: Results From the IFCT-1703 R2D2 Trial.
Mazieres J, Lafitte C, Ricordel C, Greillier L, Negre E, Zalcman G, Domblides C, Madelaine J, Bennouna J, Mascaux C, Moro-Sibilot D, Pinquie F, Cortot AB, Otto J, Cadranel J, Langlais A, Morin F, Westeel V, Besse B
J Clin Oncol, 40(7):719-728, 24 Jan 2022
Cited by: 30 articles | PMID: 35073148
Add to export list
A Case Report of Successful Treatment With Crizotinib to Overcome Resistance to Osimertinib in an EGFR Mutated Non-Small-Cell Lung Cancer Patient Harboring an Acquired MET Exon 14 Mutation.
Pinquie F, Cortot AB, Chevalier LM, Morel A, Sandrini J, Guguen C, Morvan B, Molinier O
Clin Lung Cancer, 23(2):e131-e134, 13 Jun 2021
Cited by: 4 articles | PMID: 34548228
Add to export list
Management of lung cancer patients' quality of life in clinical practice: a Delphi study.
Westeel V, Bourdon M, Cortot AB, Debieuvre D, Toffart AC, Acquadro M, Arnould B, Lambert J, Cotte FE, Gaudin AF, Lemasson H
ESMO Open, 6(4):100239, 10 Aug 2021
Cited by: 3 articles | PMID: 34388690 | PMCID: PMC8363823
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
First-Line Afatinib plus Cetuximab for EGFR-Mutant Non-Small Cell Lung Cancer: Results from the Randomized Phase II IFCT-1503 ACE-Lung Study.
Cortot AB, Madroszyk A, Giroux-Leprieur E, Molinier O, Quoix E, Bérard H, Otto J, Rault I, Moro-Sibilot D, Raimbourg J, Amour E, Morin F, Hureaux J, Moreau L, Debieuvre D, Morel H, Renault A, Pichon E, Huret B, [...] Cadranel J
Clin Cancer Res, 27(15):4168-4176, 24 May 2021
Cited by: 6 articles | PMID: 34031056
Add to export list
When the MET receptor kicks in to resist targeted therapies.
Fernandes M, Jamme P, Cortot AB, Kherrouche Z, Tulasne D
Oncogene, 40(24):4061-4078, 24 May 2021
Cited by: 12 articles | PMID: 34031544
Add to export list Review
Salvage Immunotherapy With Pembrolizumab in Patients Hospitalized for Life-Threatening Complications of NSCLC.
Roborel de Climens F, Chouaid C, Poulet C, Leroy V, Stoven L, Cortot AB, Dhalluin X, Gauvain C
JTO Clin Res Rep, 2(5):100147, 19 Jan 2021
Cited by: 3 articles | PMID: 34590015 | PMCID: PMC8474254
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC

1-25 of 85 results

1 2 3 Next ...

Search life-sciences literature (45,104,931 articles, preprints and more)

Search results

Capmatinib efficacy for METex14 non-small cell lung cancer patients: Results of the IFCT-2104 CAPMATU study.

Faecalibaterium prausnitzii strain EXL01 boosts efficacy of immune checkpoint inhibitors.

Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study.

MET variants with activating N-lobe mutations identified in hereditary papillary renal cell carcinomas still require ligand stimulation

Histo-Molecular Factors of Response to Combined Chemotherapy and Immunotherapy in Non-Small Cell Lung Cancers.

Characterization of 164 patients with NRAS mutated non-small cell lung cancer (NSCLC).

Transforming properties of MET receptor exon 14 skipping can be recapitulated by loss of the CBL ubiquitin ligase binding site.

Tepotinib Treatment in Patients With MET Exon 14-Skipping Non-Small Cell Lung Cancer: Long-term Follow-up of the VISION Phase 2 Nonrandomized Clinical Trial.

Prolonging lung cancer response to EGFR inhibition by targeting the selective advantage of resistant cells

MET exon 14 skipping mutation is a hepatocyte growth factor (HGF)-dependent oncogenic driver in vitro and in humanised HGF knock-in mice.

MET Exon 14 Skipping in NSCLC: A Systematic Literature Review of Epidemiology, Clinical Characteristics, and Outcomes.

Response to Capmatinib in a MET Fusion-positive Cholangiocarcinoma.

PD-1/PD-L1 inhibitor activity in patients with gene-rearrangement positive non-small cell lung cancer-an IMMUNOTARGET case series.

Brief Report: First-line Pembrolizumab in Metastatic Non-Small Cell Lung Cancer Habouring MET Exon 14 Skipping Mutation and PD-L1 ≥50% (GFPC 01-20 Study).

Paclitaxel-bevacizumab combination in advanced non-squamous non-small-cell lung cancer (NSCLC): AVATAX, a retrospective multicentric study.

Safety of Tepotinib in Patients With MET Exon 14 Skipping NSCLC and Recommendations for Management.

Lorlatinib for advanced anaplastic lymphoma kinase-positive non-small cell lung cancer: Results of the IFCT-1803 LORLATU cohort.

Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice.

Brigatinib for Pretreated, ALK-Positive, Advanced Non-Small-Cell Lung Cancers: Long-Term Follow-Up and Focus on Post-Brigatinib Lorlatinib Efficacy in the Multicenter, Real-World BrigALK2 Study.

Combination of Trastuzumab, Pertuzumab, and Docetaxel in Patients With Advanced Non-Small-Cell Lung Cancer Harboring HER2 Mutations: Results From the IFCT-1703 R2D2 Trial.

A Case Report of Successful Treatment With Crizotinib to Overcome Resistance to Osimertinib in an EGFR Mutated Non-Small-Cell Lung Cancer Patient Harboring an Acquired MET Exon 14 Mutation.

Management of lung cancer patients' quality of life in clinical practice: a Delphi study.

First-Line Afatinib plus Cetuximab for EGFR-Mutant Non-Small Cell Lung Cancer: Results from the Randomized Phase II IFCT-1503 ACE-Lung Study.

When the MET receptor kicks in to resist targeted therapies.

Salvage Immunotherapy With Pembrolizumab in Patients Hospitalized for Life-Threatening Complications of NSCLC.

Partnerships & funding